This is the property of 2016 CRIT/FIT. Permission is required to duplicate.

Opioids Research to Practice

CRIT/FIT 2016

April 2016

Daniel P. Alford, MD, MPH Associate Professor of Medicine Assistant Dean, Continuing Medical Education Director, Clinical Addiction Research and Education (CARE) Unit





Boston University School of Medicine






- 32 yo female brought in after "heroin overdose"
- Brisk response to IV naloxone 0.4 mg
- Re-sedation after 1 hr requiring repeat naloxone
- Arm cellulitis at injection drug use site
- Admitted for "drug overdose", "persistent altered mental status" and "arm cellulitis"

Why is heroin so pleasurable ?


- Heroin is highly lipid soluble
- Crosses blood brain barrier within 15 seconds="rush"
- After IV administration 68% heroin in brain compared to <5% of morphine
- Within 30 minutes metabolized to morphine
- HEROIN is a prodrug of MORPHINE





Analysis and ONDCP

Natural History of Opioid Use Disorder



Conflicting Priorities...

AIDS PLEADE PLEADE PLEADE PLEADE PLEADE PLEADE AUX AUX AUX AUX AUX AUX AUX AUX AUX AUX	Walker's name street address city/state/zip telephone (day) (eve) My fundraising goal is: \$200 T-shirt \$500 Sweatshirt \$750 Canvas attaché \$1,500 New Balance athletic shoes \$2,500 Polaroid Impulse camera and film
deductible. Thank you!	Amount Amount
Sponsor's name Address/city/state/zip	pledged paid
"I WILL RETURN AT	IS OR HAVE TO LEAVE HONHOR I PROMISE YOU
3 J 4 5 .	BOT J KNOW YOU WOULD HAVE HOT LET ME DO SEE XOO BJ DINNER TIME PROMISE.
spspspsbabonengte fornal a	t pts nightstond table.

¢


Case continued

Substance use history


- ½ gram of heroin/day
- Intranasal use for 6 months then IV for 7 years
- Had been in recovery for 2 years by going to NA but relapsed 3 months ago
- Denies sharing needles
- History of 10 detox's, no maintenance treatment
- No other drug, alcohol or tobacco use
- HIV and hepatitis C negative
- Unemployed elementary school teacher
- Lives with husband (in recovery) and 2 young children
- Now complaining of opioid withdrawal
 - How will you assess and treat her?

Which is <u>NOT</u> a sign of opioid withdrawal?

- 1. Vomiting
- 2. Diarrhea
- 3. Pinpoint pupils
- 4. Rhinorrhea
- 5. Lacrimation
- 6. Piloerection




Opioid Withdrawal Assessment



Clinical Opiate Withdrawal Scale (COWS): *pulse, sweating, restlessness & anxiety, pupil size, aches, runny nose & tearing, GI sx, tremor, yawning, gooseflesh (score 5-12 mild, 13-24 mod, 25-36 mod sev, 36-48 severe)*

How is acute opioid withdrawal treated on your inpatient service?

- 1. Clonidine
- 2. Methadone
- 3. Buprenorphine
- 4. Don't know
- 5. Other



Inpatient Goals

- Prevent/treat acute opioid withdrawal
 - Inadequate treatment may prevent full treatment of medical/surgical condition
- Do not expect to <u>cure</u> opioid dependence during this hospital stay
 - Withholding opioids will not cure patient's addiction
 - Giving opioids will not worsen patient's addiction
- Diagnose and treat medical illness
- Initiate substance abuse treatment referral



 Methadone or buprenorphine (more expensive) are the best choices!

• Other

- Clonidine (hyperadrenergic state)
- + NSAIDS (muscle cramps and pain)
- + Benzodiazepines (insomnia)
- + Dicyclomine (abdominal cramps)
- + Bismuth subsalicylate (diarrhea)

- Assess signs and symptoms of acute opioid withdrawal
- Reassure patient
- Discuss specific dose and goals openly with patient and nursing staff
- Don't use heroin : methadone conversions

- Start with 20 mg of methadone
- Reassess q 2-3 hours, give additional 5-10 mg until withdrawal signs abate
- Do not exceed 40 mg in 24 hours
- Monitor for CNS and respiratory depression

- On following day, give total dose QD
- Goal is to alleviate acute withdrawal
- Patient will continue to crave opioids
- Discuss taper vs maintained dose w/ pt daily
- Referral for long-term substance abuse treatment

Maintained dose option

- Give same dose each daily including day of discharge
- Allows 24-36 hour withdrawal-free period after d/c
- Tapered dose option
 - If patient requests a taper, decrease by 5 mg per day and stop taper if patient requests it
 - Don't prolong hospitalization to complete taper


Don't give a prescription for methadone


Case continued

- Hospital course
- Arm Cellulitis treated with IV Vancomycin
- Opioid withdrawal
 - Day 1 Methadone 20 mg
 - ■<u>Day 2</u>
 - Very anxious, demanded increase in methadone dose
 - Was off the floor for 2 hours
 - Repeat urine drug test was positive for "opiates"

All of the following are possible explanations for her <u>opiate positive</u> drug test <u>EXCEPT</u>?

- 1. Illicit opioid (heroin) use during hospitalization
- 2. Heroin use prior to admission
- Hydromorphone
 (Dilaudid) given for pain
 last night
- 4. Methadone given during hospitalization





Case continued

6 months later

- She presents to your primary care clinic requesting treatment for her heroin addiction
- She has been using heroin since the day she left the hospital

Case continued

Recommended options from primary care

- Narcotics Anonymous (NA)
- Clonidine + NSAID + benzodiazepine + ...
- Naltrexone (po or injectable)
- Buprenorphine maintenance (if waivered)
- Overdose prevention education and naloxone
- Referral
 - Detoxification program
 - Needle exchange
 - Acupuncture
 - Outpatient counseling
 - Methadone maintenance
 - Buprenorphine maintenance (if not waivered)

Opioid Detoxification Outcomes

- Low rates of retention in treatment
- High rates of relapse post-treatment
 - < 50% abstinent at 6 months</p>
 - < 15% abstinent at 12 months</p>
 - Increased rates of overdose due to decreased tolerance

O'Connor PG JAMA 2005 Mattick RP, Hall WD. Lancet 1996 Stimmel B et al. JAMA 1977

Reasons for Relapse

Protracted abstinence syndrome

- Secondary to derangement of endogenous opioid receptor system
- Symptoms
 - Generalized malaise, fatigue, insomnia
 - Poor tolerance to stress and pain
 - Opioid craving
- Conditioned cues (triggers)
- Priming with small dose of drug

Pharmacotherapy


• Goals

- Alleviate physical withdrawal
- Opioid blockade
- Alleviate drug craving
- Normalized deranged brain changes and physiology

• Some options

- Naltrexone (opioid antagonist)
- Methadone (full opioid agonist)
- Buprenorphine (partial opioid agonist)

Opioid Agonist Treatment (OAT)



Naltrexone

- Pure opioid antagonist
- Oral naltrexone
 - Well tolerated, safe
 - Duration of action 24-48 hours
 - FDA approved 1984
- Injectable naltrexone (Vivitrol[®])
 - IM injection (w/ customized needle) once/month
 - FDA approved 2010
 - Patients must be opioid free for a minimum of 7-10 days before treatment

Oral Naltrexone

- 10 RCTs ~700 participants to naltrexone alone or with psychosocial therapy compared with psychosocial therapy alone or placebo
 - No clear benefit in treatment retention or relapse at follow up
- Benefit in highly motivated patients
 - Impaired physicians > 80% abstinence at 18 months

Cochrane Database of Systematic Reviews 2006

Injectable Naltrexone (XR-NTX)

- Multicenter (13 sites in Russia) Funded by Alkermes
- DB RPCT, 24 wks, n=250 w/ opioid dependence
- XR-NTX vs placebo, all offered biweekly individual drug counseling
- Weeks of confirmed abstinence (90% vs 35%)
- Patients with confirmed abstinence (36% vs 23%)
- Craving (-10 vs +0.7)

Methadone Hydrochloride

- Full opioid agonist
- PO onset of action 30-60 minutes
- Duration of action
 - 24-36 hours to treat opioid addiction
 - 6-8 hours to treat pain
- Proper dosing for opioid addiction
 - 20-40 mg for acute withdrawal
 - > 80 mg for craving, "opioid blockade"

Methadone Maintenance Over 45 Years of Experience...

A Medical Treatment for Diacetylmorphine (Heroin) Addiction

A Clinical Trial With Methadone Hydrochloride

Vincent P. Dole, MD, and Marie Nyswander, MD

A group of 22 patients, previously addicted to diacetylmorphine (heroin), have been stabilized with oral methadone hydrochloride. This medication appears to have two useful effects: (1) relief of narcotic hunger, and (2) induction of sufficient tolerance to block the euphoric effect of an average illegal dose of diacetylmorphine. With this medication, and a comprehensive program of rehabilitation, patients have shown marked improvement; they have returned to school, obtained jobs, and have become reconciled with their families. Medical and psychometric tests have disclosed no signs of toxicity, apart from constipation. This treatment requires careful medical supervision and many social services. In our opinion, both the medication and the supporting program are essential.

ough review of evidence available in 1957.1 concluded that "The advisability of establishing clinics or some equivalent system to dispense opiates to addicts cannot be settled on the basis of objective facts. Any position taken is necessarily based in part on opinion, and on this question opinions are divided." With respect to previous trials of maintenance treatment, the Council found that "Assessment of the operations of the narcotic dispensaries between 1919 and 1923 is difficult because of the paucity of published material. Much of the small amount of data that is available is not sufficiently objective to be of great value in formulating any clear-cut opinion of the purpose of the clinics, the way in which they operated, or the results attained." No new studies bearing on the question



Methadone Treatment Marks 40 Years

Bridget M. Kuehn

CORTY YEARS AND COUNTLESS Political firestorms after it was first introduced, methadone maintenance for the treatment of opioid addiction remains a standard therapy in the field of addiction treatment.

The publication on August 23, 1965, of positive results from a small clinical trial of methadone as a treatment for heroin addiction in JAMA marked a sea change in the treatment of addiction (Dole and Nyswander. JAMA. 1965; 193:646-650). The study, conducted at Rockefeller University in New York City by Vincent P. Dole, MD, and the late Marie E. Nyswander, MD, suggested that a medication could be used to control the cravings and withdrawal that often lead to relapse in individuals with opioid addiction who attempt to quit.

The work, along with subsequent research by Dole, an endocrinologist, Nyswander, a psychiatrist, and colleagues established the concept of opioid addiction as a chronic disease, similar to diabetes, that as such required



now head of the Laboratory of the Biology of Addictive Diseases at Rockefeller University, explained that work conducted by the group in 1964 and published in 1966 established that methadone blocked the effects of heroin and stabilized patients, who prior to treatment oscillated between feeling



done treatment, the ap always struggled for accep the forces of public opini tics. "There is a stigma aq tions, addicts, and—sadly providers," said Kreek, a supporter of the methado

"THE FARM"


Methadone maintenance resented a reversal of the tr approach to treating dru said David F. Musto, MD turer at Yale and expert policy. A 1919 Supreme sion had established tha alone did not justify physing addicts with opioids. B cision, some physicians ha acting opioids to treat indi opioid addiction.

The Drug Enforcement tion, in fact, considered Dc illegal and had threatened him prior to the 1965 pub defy the US government wa litical courage," said Jerom who became the first natio

JAMA 1965

Methadone Maintenance Dosing

Figure 1 - Heroin Use in Past 30 Days 407 MM Patients by Current Methadone Dose







FIGURE 7.1. Impact of methadone maintenance treatment on intravenous drug use for 388 male methadone patients in six programs.


Ball JC, Ross A. The effectiveness of methadone maintenance treatment, 1991

Effects of Psychosocial Services




McLellan, AT et.al, J AMA 1993

What is the single best question to assess a patient's success on methadone maintenance treatment?



- 3. Are you compliant with methadone treatment?
- 4. How long have you been on methadone treatment?



Methadone Maintenance Treatment Highly Structured

- Daily nursing assessment
- Weekly individual and/or group counseling
- Random supervised drug testing
- Psychiatric services
- Medical services
- Methadone dosing
 - Observed daily \Rightarrow "Take homes"

In a Comprehensive Rehabilitation Program...

- Increases overall survival
- Increases treatment retention
- Decreases illicit opioid use
- Decreases hepatitis and HIV seroconversion
- Decreases criminal activity
- Increases employment
- Improves birth outcomes


Methadone Maintenance Limitations

Highly regulated - Narcotic Addict Treatment Act 1974

- Created methadone clinics (Opioid Treatment Programs)
- Separate system not involving primary care or pharmacists
- Limited access
- Inconvenient and highly punitive
- Mixes stable and unstable patients
- Lack of privacy
- No ability to "graduate" from program
- Stigma

Methadone Maintenance Still controversial...

"I don't believe in methadone...substituting one drug for another...liquid handcuffs..."



DATA 2000 and Buprenorphine

2000: Drug Addiction Treatment Act (DATA) 2000

 Allows <u>qualified physician</u> to prescribe <u>scheduled III - V</u>, narcotic <u>FDA approved</u> for opioid maintenance or detoxification treatment limit <u>30 patients per practice</u>

2002: Suboxone and Subutex FDA approved
2005: Limit to <u>30 patients per physician</u>
2007: Limit to <u>100 patients per physician</u> after 1 year

Physician Qualifications

The <u>physician</u> is licensed under State law and "<u>qualified</u>" based on <u>one</u> of the following:

Certified in Addiction Psychiatry or Medicine

Completed <u>eight hours</u> of training


List of trainings: <u>www.buprenorphine.samhsa.gov</u>

Online training: <u>www.buppractice.com</u>


Buprenorphine

- Buprenorphine (Subutex or generic) "mono"
- Buprenorphine + naloxone (Suboxone)"combo"
 - Schedule III
 - Sublingual tablets, film
 - Treatment of opioid dependence
 - High receptor affinity
 - Slow dissociation
 - Ceiling effect for respiratory depression

Opioid Blockade



Buprenorphine Maintenance vs Taper



Kakko J et al. Lancet 2003

Buprenorphine Efficacy

- Studies (RCT) show buprenorphine more effective than placebo and equally effective to moderate doses (80 mg) of methadone on primary outcomes of:
 - Abstinence from illicit opioid use
 - Retention in treatment
 - Decreased opioid craving


Johnson et al. NEJM 2000 Fudala PJ et al. NEJM 2003 Kakko J et al. Lancet 2003

Methadone vs Buprenorphine

9 OTPs n=1,267


RCT buprenorphine vs methadone

6 month retention



Hser Y, et al. Addiction. 2014

Patients with OUD Receiving Medications 2002-2013



Source: IMS Total Patient Tracker, Sep 2014. Buprenorphine data exclude forms indicated for pain. Oral naltrexone factored for opioid dependence use only (40% factor provided by Alkermes). Methadone patients, N-SSATS

OUD Treatment Gap: 2012 5,197,000 3.7 million 1,462,069

Opioid and Heroin Patients Receiving Past Month Use of Pain Relievers or MAT* Heroin NSDUH 2012

* Number of individuals receiving buprenorphine or naltrexone from IMS plus number of patients receiving methadone from NSSATS. Source: IMS Total Patient Tracker, Sept 2014 and SAMHSA NSSATS. Buprenorphine data exclude forms indicated for pain. Oral naltrexone factored for opioid dependence use. Methadone patients from SAMHSA, N-SSATS 2012.

Opioid Maintenance Treatment and Acute Pain Management

- Patients on opioid maintenance treatment (i.e. methadone or buprenorphine) have less pain tolerance then matched controls
- Patients who are physically dependent on opioids (i.e. methadone or buprenorphine) must be maintained on daily equivalence before ANY analgesic effect is realized with opioids used for acute pain management
- Opioid analgesic requirements are often higher due to increased pain sensitivity and opioid cross tolerance

Alford DP, Compton P, Samet JH. Ann Intern Med 2006